Xanthelasma Palpebrarum

Xanthelasma palpebrarum is the most common cutaneous xanthoma, arising from focal accumulation of lipid-laden foam cells (histiocytes) within the superficial dermis of the periocular skin. It presents as soft, flat to slightly elevated, yellow-white plaques most commonly at the medial upper eyelids, though lower lid and bilateral medial canthal involvement occurs.

Prevalence in population studies is approximately 4% in adults (Christoffersen et al., BMJ 2011), with a slight female predominance and peak onset in the fourth to sixth decades. The condition is benign — no malignant potential — but is clinically important because it may indicate underlying dyslipidaemia or elevated cardiometabolic risk even in patients with apparently normal standard lipid panels.

• Disordered lipid metabolism (primary): elevated LDL-C, total cholesterol, or triglycerides drive increased circulating lipoprotein load, promoting dermal foam cell accumulation.
• Normolipidaemic xanthelasma: occurs in a substantial subgroup (~25–50%) without overt dyslipidaemia on standard fasting panels; atherogenic lipid subfractions (elevated ApoB, small dense LDL, Lp(a)) or qualitative lipoprotein abnormalities may still be present.
• Familial dyslipidemias: familial hypercholesterolaemia (FH), familial combined hyperlipidaemia, and type III hyperlipoproteinaemia (dysbetalipoproteinaemia) are important causes.
• Secondary dyslipidaemia: diabetes mellitus and insulin resistance, hypothyroidism, nephrotic syndrome, cholestatic liver disease, and obesity all impair lipid clearance.
• Local periocular tissue factors: the eyelid dermis is among the thinnest skin in the body; high vascularity and loose connective tissue architecture may favour lipoprotein extravasation and foam cell trapping at this specific site.

1. Lipoprotein extravasation: circulating lipoproteins — particularly LDL and modified/oxidised LDL — leak from dermal microvasculature into the periocular interstitium.
2. Scavenger receptor-mediated uptake: resident macrophages/monocytes internalise modified lipoproteins (primarily oxidised LDL) via SR-A and CD36 scavenger receptors, bypassing the normal ApoB/LDL-receptor pathway.
3. Foam cell formation: lipid-laden histiocytes accumulate in the superficial reticular dermis — characteristically around vessels and adnexal structures — forming the histologic hallmark of xanthelasma.
4. Plaque consolidation: progressive accumulation of foam cells produces the flat yellow plaque; lesions may enlarge over years and become confluent near the medial canthus.
5. Recurrence after removal: persistent systemic lipid excess continues to drive lipoprotein extravasation, enabling re-accumulation unless underlying dyslipidaemia is corrected.

Histology: collections of foamy histiocytes (CD68+, lipid vacuoles on H&E) in the superficial reticular dermis, often along vessels and around pilosebaceous units; no nuclear atypia; no invasion.

• Age: peak onset fourth to sixth decade; uncommon before age 30 except in familial hypercholesterolaemia.
• Sex: slight female predominance in most cohort studies.
• Dyslipidaemia: elevated LDL-C, non-HDL-C, total cholesterol, or triglycerides; low HDL-C; elevated ApoB or Lp(a).
• Diabetes mellitus and metabolic syndrome: insulin resistance impairs LDL catabolism and promotes dyslipidaemia.
• Obesity: central adiposity associated with atherogenic dyslipidaemia and elevated triglycerides.
• Hypothyroidism: markedly elevates LDL-C via reduced LDL-receptor expression; TSH should always be checked.
• Nephrotic syndrome: secondary hyperlipidaemia from reduced oncotic pressure and hepatic compensatory lipoprotein synthesis.
• Familial hypercholesterolaemia (FH): autosomal dominant condition; heterozygous FH prevalence 1:250 globally; xanthelasma in younger patients is a sentinel feature.
• Family history of premature ASCVD: first-degree relative with MI or stroke before age 55 (men) or 65 (women).
• Smoking: promotes oxidative modification of LDL and reduces HDL — indirect lipid risk contribution.

• Flat to slightly raised, yellow to yellow-white plaques — classically at the medial upper eyelids adjacent to the medial canthus.
• Soft, non-tender, smooth-surfaced lesions with well-defined borders; no induration, ulceration, or hyperkeratosis.
• Bilateral and roughly symmetric distribution is characteristic; unilateral or asymmetric lesions should raise diagnostic uncertainty.
• Lower medial lid plaques — often smaller — occur in progressive or more extensive disease.
• No madarosis, lash distortion, lid margin disruption, or destructive architectural changes (presence of any of these warrants biopsy to exclude malignancy).
• Occasionally visible corneal arcus (lipid deposition in peripheral corneal stroma) co-presents with xanthelasma — another marker of dyslipidaemia, especially if present before age 45.
• Look for tendon xanthomata (Achilles, extensor tendons of hands) if familial hypercholesterolaemia is suspected.

• Usually asymptomatic — the lesion itself causes no pain, visual disturbance, or ocular symptoms.
• Primary presentation is cosmetic concern: patients notice the yellow discoloration and seek assessment for appearance or anxiety about systemic disease.
• Mild psychosocial impact — self-consciousness, social avoidance, or reduced confidence, particularly in younger patients.
• Occasional awareness of mild periocular heaviness or fullness in patients with large or extensive confluent plaques.
• Rare mild surface irritation if the lesion edge rubs against adjacent skin folds or is aggravated by cosmetic use.
• No discharge, tearing, blurred vision, or ocular surface symptoms directly attributable to xanthelasma.

• Lesion progression: plaques enlarge slowly over years; adjacent lesions may coalesce into confluent periocular xanthomata, complicating future removal.
• Cosmetic distress and psychosocial impact: reduced self-confidence, avoidance of social situations, or patient anxiety regarding systemic disease — can be significant even with small lesions.
• Recurrence after treatment: high recurrence rate (up to 50–80% at 5 years) across all modalities if underlying dyslipidaemia is uncontrolled; patients must be counselled on this before any procedure.
• Post-procedure complications: dyspigmentation (hypo- or hyperpigmentation, especially in darker skin types), surface contour irregularity, hypertrophic scar, or rare lid retraction/ectropion if aggressive excision near the canthal angle.
• Missed systemic diagnosis: failure to perform lipid and cardiometabolic screening misses an opportunity to identify and treat elevated cardiovascular risk — the most clinically significant complication.

Xanthelasma can serve as a cutaneous marker of cardiometabolic risk even when standard fasting lipid panels are within normal limits. Population data from Christoffersen et al. (BMJ 2011) demonstrated that xanthelasma was an independent predictor of myocardial infarction, ischaemic heart disease, and early death after adjusting for traditional cardiovascular risk factors.

Diagnosis is clinical in typical cases. Bilateral symmetric yellow soft plaques at the medial upper eyelids in a middle-aged adult are pathognomonic. Biopsy is reserved for atypical presentations.

• Benign lesion — no malignant transformation: xanthelasma has no potential to become cancerous; prognosis of the eyelid lesion itself is excellent.
• Cosmetic outcome: generally good with appropriate technique and operator experience in Grade I–II lesions; Grade III confluent plaques have higher procedural risk and more complex reconstruction needs.
• Recurrence: 40–80% at 5 years depending on modality and lipid control; more advanced or bilateral lesions recur more frequently; optimised lipid management may reduce but not eliminate recurrence risk.
• Cardiovascular prognosis: determined by the systemic cardiometabolic risk profile — not by the xanthelasma itself. Identification and treatment of dyslipidaemia, hypertension, diabetes, and smoking reduces long-term ASCVD morbidity and mortality.
• Long-term surveillance: patients require ongoing lipid monitoring, cardiometabolic review, and periodic periocular assessment for new lesions — particularly if treatment has been performed.